Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Classic maple syrup urine disease (classic MSUD) is the most severe and probably common form of MSUD characterized by a maple syrup odor in the cerumen at birth, poor feeding, lethargy and focal dystonia, followed by progressive encephalopathy and central respiratory failure if untreated.
Biomarker and diagnostic research for classic maple syrup urine disease has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for classic maple syrup urine disease.
18 publications have been identified in PubMed for classic maple syrup urine disease. Research spans Case Report / Case Series (22%), Review / Meta-Analysis (17%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 4 | 22% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:09 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about classic maple syrup urine disease
Research summaries
3 |
17% |
Clinical study results | 3 | 17% |
New treatment approaches | 3 | 17% |
Testing and diagnosis research | 2 | 11% |
Laboratory research | 2 | 11% |
Disease patterns and progression | 1 | 6% |
Brigatti KW (2026). [PMID: 42127902](https://pubmed.ncbi.nlm.nih.gov/42127902/). *Cell Rep Med*. [Gene Therapy / Novel Therapeutics]
Rodrigues A (2026). [PMID: 41564618](https://pubmed.ncbi.nlm.nih.gov/41564618/). *Molecular genetics and metabolism*. [Gene Therapy / Novel Therapeutics]
Tosi M (2026). [PMID: 41928300](https://pubmed.ncbi.nlm.nih.gov/41928300/). *Orphanet J Rare Dis*. [Clinical Trial Publication]
Hassan SA (2026). [PMID: 32491705](https://pubmed.ncbi.nlm.nih.gov/32491705/). *Unknown Journal*. [Review / Meta-Analysis]
Upadia J (2025). [PMID: 40823510](https://pubmed.ncbi.nlm.nih.gov/40823510/). *Molecular genetics and metabolism reports*. [Case Report / Case Series]
Hassan I (2025). [PMID: 41450887](https://pubmed.ncbi.nlm.nih.gov/41450887/). *Frontiers in pediatrics*. [Case Report / Case Series]
Wang J (2025). [PMID: 40009698](https://pubmed.ncbi.nlm.nih.gov/40009698/). *Science translational medicine*. [Gene Therapy / Novel Therapeutics]
Garrett R (2025). [PMID: 41635633](https://pubmed.ncbi.nlm.nih.gov/41635633/). *Molecular genetics and metabolism reports*. [Diagnostic / Biomarker]
Di Costanzo M (2025). [PMID: 40491588](https://pubmed.ncbi.nlm.nih.gov/40491588/). *Frontiers in nutrition*. [Epidemiology / Natural History]
Mishra N (2025). [PMID: 40132917](https://pubmed.ncbi.nlm.nih.gov/40132917/). *BMJ case reports*. [Review / Meta-Analysis]